NBE-002

News alerts, weekly reports and conference planners

Company:

Boehringer Ingelheim, Sotio

Drug class:

DNA replication inhibitor, ROR1-targeted antibody-drug conjugate

Related drugs:

‹

›

ROR1 positive	Leukemia	ROR1 positive	Leukemia	NBE-002 Sensitive: D – Preclinical NBE-002 Sensitive : D	NBE-002 Sensitive: D – Preclinical NBE-002 Sensitive : D
ROR1 expression	Triple Negative Breast Cancer	ROR1 expression	Triple Negative Breast Cancer	NBE-002 Sensitive: D – Preclinical NBE-002 Sensitive : D	NBE-002 Sensitive: D – Preclinical NBE-002 Sensitive : D

Associations
(2)